GALT Stock Price
Galectin Therapeutics Inc.
GALT stock price is $3.60 (-0.55% on the day), giving Galectin Therapeutics Inc. a market cap of $365.79M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
GALT Stock Overview
- Price
- $3.60
- Previous close
- $3.62
- Open
- $3.62
- Market cap
- $365.79M
- P/E ratio
- -11.9
- 52-week range
- $2.02 - $7.13
- 1-year price target
- $11.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NSC
- MarketXLS Rank
- 38
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GALT | $3.60 | -0.6% | 82.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Galectin Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW